New triple therapy aims to shrink pancreatic tumors before surgery
NCT ID NCT07469956
First seen Mar 15, 2026 · Last updated Jun 23, 2026 · Updated 15 times
Summary
This phase 2 trial tests whether giving a combination of surufatinib (a targeted therapy), toripalimab (an immunotherapy), and chemotherapy before surgery can help people with high-risk or borderline resectable pancreatic cancer. The study will enroll 30 participants and track how many are free of cancer events after 12 months. The goal is to see if this approach makes tumors easier to remove and improves survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER RESECTABLE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen University Cancer Center
Guangzhou, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
surufatinib, toripalimab, and chemotherapy (mFOLFIRINOX)
What this could lead to
If this works, it could shrink pancreatic tumors enough to allow successful surgery, potentially improving long-term survival for patients with hard-to-treat pancreatic cancer.
What could go wrong
This is a small, early-phase trial with only 30 people, so results may not apply broadly. The combination of drugs can cause serious side effects, and it is not yet known if it will improve outcomes.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.